Literature DB >> 29085770

Should AFP (or any biomarkers) be used for HCC surveillance?

Hager F Ahmed Mohammed1, Lewis R Roberts1.   

Abstract

A PURPOSE OF REVIEW: To address the controversy around the use of biomarkers for hepatocellular carcinoma (HCC) surveillance in individuals with cirrhosis or chronic hepatitis B who are at risk for development of liver cancer. B RECENT
FINDINGS: Recent studies suggest that surveillance for hepatocellular carcinoma is beneficial, even after adjustment for lead time and other biases. Alpha fetoprotein (AFP) is complementary to ultrasound (US) in surveillance, particularly in obese patients and patients with infiltrative tumors. US and AFP are both associated with harms to patients from false positive over-diagnosis, with US appearing to cause greater harms. Including patient demographic characteristics and additional biomarkers into diagnostic models is beneficial. Recent studies emphasize the advantage of time trends in biomarkers over single cross-sectional measurements. C
SUMMARY: AFP and other biomarkers are complementary to US in surveillance for HCC, especially when applied in models including patient variables and incorporating time trends in biomarker levels. With advances in genetic and molecular analysis of tumors, we may be poised at the cusp of a revolution in HCC surveillance.

Entities:  

Keywords:  AFP-L3; Cirrhosis; Des-gamma carboxy prothrombin; GALAD; Hepatocellular Carcinoma; Liver Cancer; Screening

Year:  2017        PMID: 29085770      PMCID: PMC5659201          DOI: 10.1007/s11901-017-0349-7

Source DB:  PubMed          Journal:  Curr Hepatol Rep        ISSN: 2195-9595


  91 in total

1.  Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis.

Authors:  Hager A Ahmed Mohammed; Ju Dong Yang; Nasra H Giama; Jonggi Choi; Hawa M Ali; Kristin C Mara; William S Harmsen; Russell H Wiesner; Michael D Leise; Terry M Therneau; Lewis R Roberts
Journal:  Liver Cancer       Date:  2016-12-17       Impact factor: 11.740

2.  Length time bias in surveillance for hepatocellular carcinoma and how to avoid it.

Authors:  Alessandro Cucchetti; Francesca Garuti; Antonio Daniele Pinna; Franco Trevisani
Journal:  Hepatol Res       Date:  2016-03-30       Impact factor: 4.288

3.  Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma.

Authors:  K Hayashi; T Kumada; S Nakano; I Takeda; K Sugiyama; S Kiriyama; Y Sone; A Miyata; H Shimizu; S Satomura
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

4.  A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Jessica A Davila; Jennifer Kramer; Peter Richardson
Journal:  Gastroenterology       Date:  2014-01-23       Impact factor: 22.682

5.  Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.

Authors:  Sarah Berhane; Hidenori Toyoda; Toshifumi Tada; Takashi Kumada; Chiaki Kagebayashi; Shinji Satomura; Nora Schweitzer; Arndt Vogel; Michael P Manns; Julia Benckert; Thomas Berg; Maria Ebker; Jan Best; Alexander Dechêne; Guido Gerken; Joerg F Schlaak; Arndt Weinmann; Marcus A Wörns; Peter Galle; Winnie Yeo; Frankie Mo; Stephen L Chan; Helen Reeves; Trevor Cox; Philip Johnson
Journal:  Clin Gastroenterol Hepatol       Date:  2016-01-13       Impact factor: 11.382

6.  A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.

Authors:  Judith M Ertle; Dominik Heider; Marc Wichert; Benedikt Keller; Robert Kueper; Philip Hilgard; Guido Gerken; Joerg F Schlaak
Journal:  Digestion       Date:  2013-02-08       Impact factor: 3.216

7.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Authors:  Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

8.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study.

Authors:  Hla-Hla Thein; Michael A Campitelli; Latifa T Yeung; Ahmad Zaheen; Eric M Yoshida; Craig C Earle
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

View more
  11 in total

1.  Current Status of the GALAD and BALAD Biomarker Models for Hepatocellular Carcinoma.

Authors:  Lewis R Roberts
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-12

2.  Risk Factors for Hypervascularization in Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement: A Systematic Review and Meta-analysis.

Authors:  Tae-Hyung Kim; Sungmin Woo; Sangwon Han; Chong Hyun Suh; Richard Kinh Gian Do; Jeong Min Lee
Journal:  Acad Radiol       Date:  2020-09-20       Impact factor: 5.482

3.  Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis.

Authors:  Henry L Y Chan; Arndt Vogel; Thomas Berg; Enrico N De Toni; Masatoshi Kudo; Jörg Trojan; Anja Eiblmaier; Hanns-Georg Klein; Johannes Kolja Hegel; Ashish Sharma; Kairat Madin; Vinzent Rolny; Marcus-Rene Lisy; Teerha Piratvisuth
Journal:  JGH Open       Date:  2022-05-07

4.  Serum midkine levels for the diagnosis and assessment of response to interventional therapy in patients with hepatocellular carcinoma.

Authors:  Lin Zheng; Hailiang Li; Jinhua Huang; Jihoon Shin; Suxia Luo; Chenyang Guo; Yan Zhao; Fangkun Li
Journal:  J Interv Med       Date:  2020-10-12

5.  Hepatocellular carcinoma surveillance: current practice and future directions.

Authors:  Joseph C Ahn; Yi-Te Lee; Vatche G Agopian; Yazhen Zhu; Sungyong You; Hsian-Rong Tseng; Ju Dong Yang
Journal:  Hepatoma Res       Date:  2022-03-11

6.  AFP and CA-125 as an accurate risk factor to predict eye metastasis in hypertension patients with liver carcinoma: A STROBE-compliant article.

Authors:  Jing Tang; Li-Juan Zhang; Min Kang; Rong Huang; Hui-Ye Shu; Hong Wei; Jie Zou; Yi-Cong Pan; Qian Ling; Yi Shao
Journal:  Front Genet       Date:  2022-09-19       Impact factor: 4.772

7.  Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP.

Authors:  Young-Sun Lee; Eunjung Ko; Eileen L Yoon; Young Kul Jung; Ji Hoon Kim; Yeon Seok Seo; Hyung Joon Yim; Kyun-Hwan Kim; So Young Kwon; Jong Eun Yeon; Soon Ho Um; Kwan Soo Byun
Journal:  J Clin Med       Date:  2020-01-23       Impact factor: 4.241

8.  Identification of CDC25C as a Potential Biomarker in Hepatocellular Carcinoma Using Bioinformatics Analysis.

Authors:  Ruifeng Xun; Hougen Lu; Xianwang Wang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

9.  Molecular and genetic markers in hepatocellular carcinoma: In silico analysis to clinical validation (current limitations and future promises).

Authors:  Sarah El-Nakeep
Journal:  World J Gastrointest Pathophysiol       Date:  2022-01-22

10.  A scoring model combining serum alpha-fetoprotein and tumor size and number predicts prognosis in hepatitis B virus-related hepatocellular carcinoma patients after curative hepatectomy.

Authors:  Bai Wei; Jing-San Chen; Sheng-Li Yang; George G Chen; Hao He
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.